Trials / Conditions / Lung Cancer Stage III

Lung Cancer Stage III

18 registered clinical trials studyying Lung Cancer Stage III — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Bovine Reinforcement in Stomach, Colorectal and Lung Operation NCT06968221	Shanghai Cingularbio Co. Ltd	Phase 3
Recruiting	Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. NCT06563999	Sun Yat-sen University	Phase 2
Withdrawn	A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants NCT05358691	Rutgers, The State University of New Jersey	Phase 1
Terminated	Induction Chemo-Nivo in Unresectable Stage III NSCLC NCT06003075	Ralph G Zinner	Phase 2
Recruiting	Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC NCT06111807	University Medical Center Groningen	—
Unknown	Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management NCT06060964	University of South Carolina	EARLY_Phase 1
Unknown	Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer NCT05994339	Laibin People's Hospital	Phase 2 / Phase 3
Unknown	Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic NCT05996263	University Hospital, Brest	—
Unknown	Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer NCT06086574	University of Manchester	—
Recruiting	Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surger NCT04991025	Memorial Sloan Kettering Cancer Center	Phase 2
Completed	Resilience Measurement in Older Adults With Late-Stage Lung Cancer NCT04825912	Duke University	N/A
Active Not Recruiting	Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy NCT04305613	Abramson Cancer Center at Penn Medicine	—
Completed	Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer NCT04003246	University of Texas Southwestern Medical Center	Phase 2
Completed	Self-System Therapy for Older Adults With Lung Cancer NCT04057196	Duke University	N/A
Unknown	Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC. NCT04364776	Fondazione IRCCS Policlinico San Matteo di Pavia	—
Recruiting	Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NCT03872661	Sun Yat-sen University	Phase 2
Active Not Recruiting	Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC NCT03141359	Wake Forest University Health Sciences	Phase 2
Recruiting	COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA) NCT05258448	Odense University Hospital	—